Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.51 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.50 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.50 |
| ▸ | SLC1A1 | P43005 | 3/20 | 0.50 |
| ▸ | MMP2 | P08253 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | MMP1 | P03956 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | MMP8 | P22894 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3862569 | 1.00 | GBA1 (0.51) | GBA1SLC1A3SLC1A2SLC1A1MMP2 | |
| SCHEMBL2067895 | 1.00 | GBA1 (0.51) | GBA1SLC1A3SLC1A2SLC1A1MMP2 | |
| SCHEMBL7089076 | 0.98 | GBA1 (0.50) | GBA1SLC1A3SLC1A2SLC1A1MMP2 | |
| SCHEMBL13191678 | 0.90 | SLC1A3 (0.50) | GBA1SLC1A3SLC1A2SLC1A1MMP2 | |
| SCHEMBL7618209 | 0.89 | SLC1A3 (0.51) | GBA1SLC1A3SLC1A2SLC1A1MMP2 | |
| SCHEMBL2239236 | 0.89 | ALDH1A1 (0.53) | GBA1SLC1A3SLC1A2SLC1A1MMP2 | |
| SCHEMBL15841411 | 0.89 | SLC1A3 (0.51) | SLC1A3SLC1A2SLC1A1MMP2CA12 | |
| SCHEMBL292958 | 0.89 | ALDH1A1 (0.53) | GBA1SLC1A3SLC1A2SLC1A1MMP2 | |
| SCHEMBL15841410 | 0.89 | SLC1A3 (0.51) | SLC1A3SLC1A2SLC1A1MMP2CA12 | |
| SCHEMBL130104 | 0.89 | ALDH1A1 (0.53) | GBA1SLC1A3SLC1A2SLC1A1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119775208-A | Chiral bisimidazoline ligand containing cyclohexane skeleton structure and preparation method thereof | 北京化工大学 | 2025-04-08 | — | — | CN | disclosed |
| US-7582658-B2 | Bicyclic compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-09-01 | — | — | US | disclosed |
| US-20060069098-A1 | Bicyclic compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2006-03-30 | — | — | US | disclosed |
| EP-1300381-B1 | Process for preparing optically active alcohols | JAPAN SCIENCE & TECH AGENCY (JP) | 2006-03-08 | — | — | EP | disclosed |
| US-6642387-B2 | Dehalogenation esterification; efficient; no toxic materials | KANEKA CORPORATION (JP) | 2003-11-04 | — | — | US | disclosed |
| US-20030130521-A1 | Substituted acetylpyridine derivatives and process for the preparation of intermediates for optically active beta3 agonist by the use of the same | KANEKA CORPORATION (JP) | 2003-07-10 | — | — | US | disclosed |
| US-6515134-B1 | A production method of an optically active hydroxyethyl pyridine derivative represented by the general formula which comprises using a microorganism-derived carbonyl reducing enzyme or a culture of a microorganism having an ability of | KANEKA CORPORATION (JP) | 2003-02-04 | — | — | US | disclosed |
| EP-1153919-A1 | SUBSTITUTED ACETYLPYRIDINE DERIVATIVES AND PROCESS FOR THE PREPARATION OF INTERMEDIATES FOR OPTICALLY ACTIVE BETA3 AGONIST BY THE USE OF THE SAME | KANEKA CORPORATION (JP) | 2001-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130521-A1 | Substituted acetylpyridine derivatives and process for the preparation of intermediates for optically active beta3 agonist by the use of the same | ADRB3, ADRB2, ADRB1 | GBA1 1542/4885SLC1A3 1594/4885SLC1A2 2062/4885 |
| US-20060069098-A1 | Bicyclic compound | CRH, NR3C2, CRHR1 | GBA1 4575/4885SLC1A3 930/4885SLC1A2 495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.